These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9718357)

  • 1. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
    Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
    J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
    Bird S; Miller NJ; Collins JE; Rice-Evans CA
    J Inherit Metab Dis; 1995; 18(2):123-6. PubMed ID: 7564225
    [No Abstract]   [Full Text] [Related]  

  • 4. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E; Lindstedt S
    J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTBC as palliative treatment in chronic tyrosinaemia type I.
    Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
    J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
    [No Abstract]   [Full Text] [Related]  

  • 6. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
    Kassel R; Sprietsma L; Rudnick DA
    J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
    Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
    J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of nitisinone in tyrosine pathway disorders.
    Lock E; Ranganath LR; Timmis O
    Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising new treatment for type I tyrosinemia.
    Heubi JE
    J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
    [No Abstract]   [Full Text] [Related]  

  • 10. Alkaptonuria.
    Lorenzini S; Mannoni A; Selvi E
    N Engl J Med; 2003 Apr; 348(14):1408; author reply 1408. PubMed ID: 12672874
    [No Abstract]   [Full Text] [Related]  

  • 11. New treatment for tyrosinaemia.
    Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
    [No Abstract]   [Full Text] [Related]  

  • 12. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

  • 13. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
    Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
    J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkaptonuria: treasure your exceptions.
    Cox TM
    J Inherit Metab Dis; 2011 Dec; 34(6):1113-4. PubMed ID: 21938512
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
    Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
    Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
    Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Mitchell GA
    Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
    Gissen P; Preece MA; Willshaw HA; McKiernan PJ
    J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suitability of nitisinone for alkaptonuria.
    Häberle J
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.